Capsovision buzz

News and Updates

News Releases​

CapsoVision to Present at the 20th Annual LD Micro Main Event

October 13, 2026
SARATOGA, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior

CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®

September 28, 2026
AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system SARATOGA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company

CapsoVision to Participate in Upcoming Investor Conferences

September 3, 2026
SARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior

CapsoVision Reports Second Quarter 2026 Financial Results

August 13, 2026
SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided a business update for its second quarter ended June

CapsoVision® Announces International Launch of AI Highlights

August 3, 2026
AI-assisted review feature designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system SARATOGA, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and

CapsoVision Reports First Quarter 2026 Financial Results

May 14, 2026
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.

CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026

April 30, 2026
SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release first quarter 2026 financial results on Thursday,

CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results

March 26, 2026
SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025.

CapsoVision Announces $14 Million Private Placement Financing

March 20, 2026
Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results SARATOGA, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (the “Company”) (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy

CapsoVision to Participate in the 38th Annual ROTH Conference

March 9, 2026
- Company to participate in a fireside chat and 1x1 investor meetings on March 23, 2026 - SARATOGA, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today

CapsoVision Reports Third Quarter 2025 Financial Results

November 13, 2025
SARATOGA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its third quarter ended September 30, 2025.

CapsoVision Appoints David Garcia as Senior Vice President of Finance

November 3, 2025
Seasoned finance executive brings public company, capital markets and transaction experience to support next phase of growth SARATOGA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled

CapsoVision Reports Second Quarter 2025 Financial Results

August 14, 2025
SARATOGA, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its second quarter ended June 30, 2025.

CapsoVision Announces Closing of Initial Public Offering

July 3, 2025
CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.”

CapsoVision Announces Pricing of Initial Public Offering

July 1, 2025
CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share.

CapsoVision’s CapsoCam Plus® Capsule Endoscopy System Receives FDA Clearance for Pediatric Use, Offering a Comfortable, Child-Friendly Solution for Young Patients

January 9, 2025
CapsoVision, a leader in capsule endoscopy, has announced that its flagship product, CapsoCam Plus®, has received FDA clearance for use in pediatric patients aged two and above. This milestone enables children to benefit from the ease and accuracy of capsule endoscopy via a non-invasive, comfortable diagnostic option that reduces the stress associated with traditional capsule endoscopy procedures.

CapsoVision Offers Capsule Endoscopy Reading Service

July 15, 2023
The CapsoCam Plus® Reading Service maximizes your productivity by expediting your reports. All readers are US-based, board-certified gastroenterologists with extensive experience in the interpretation of CapsoCam Plus capsule endoscopy images.

Company Updates